Semaglutide + BPC-157 Stack

Semaglutide's biggest limitation isn't efficacy—it's tolerability. Up to 44% of subjects in clinical trials experienced nausea, and 24% reported vomiting. Many researchers have to limit their dose below the therapeutic threshold due to GI distress.

BPC-157 is derived from human gastric juice and has been extensively studied for its gastroprotective properties. It protects gastric mucosa, accelerates gut healing, and modulates the gut-brain axis. Research suggests it may:

• Reduce nausea and GI inflammation caused by GLP-1 agonists
• Protect the gastric lining during periods of reduced food intake
• Support the enteric nervous system through nitric oxide modulation

This makes BPC-157 a logical companion to semaglutide—it addresses the primary barrier to effective dosing.

This is a two-peptide stack with distinct administration routes:

• Semaglutide — Weekly subcutaneous injection for appetite suppression, insulin sensitization, and GLP-1 receptor agonism. The primary fat-loss driver.
• BPC-157 — Can be taken orally (capsule or sublingual) for direct gut protection, or via subcutaneous injection for systemic benefits. Oral BPC-157 is particularly appropriate in this stack since the target is gastrointestinal support.

Some researchers add ipamorelin to this stack for GH-mediated fat loss, but the semaglutide/BPC-157 core is effective as a standalone two-compound protocol.

Begin BPC-157 at least 1 week before starting semaglutide to establish gut protection. Titrate semaglutide slowly: 0.25 mg for 4 weeks, then 0.5 mg, increasing by 0.5 mg every 4 weeks as tolerated up to 2.4 mg.

Weeks 1–4: BPC-157 establishes gut protection. Semaglutide begins at lowest dose. Appetite reduction starts. GI side effects should be noticeably milder than semaglutide-only protocols based on anecdotal research reports.

Weeks 4–8: As semaglutide dose increases, fat loss accelerates. BPC-157 continues mitigating nausea and supporting gut health. Weight loss of 4–8 lbs is typical in this window.

Weeks 8–20: Full therapeutic semaglutide dosing reached. Research subjects report 15–20% body weight reduction over 16–20 weeks. BPC-157 may allow subjects to tolerate higher semaglutide doses than they otherwise could.

Semaglutide side effects include nausea (reduced by BPC-157), constipation, diarrhea, and injection-site reactions. Rare but serious risks include pancreatitis and gallbladder issues. BPC-157 has minimal reported side effects.

Precautions: Do not use semaglutide with personal/family history of medullary thyroid carcinoma or MEN-2 syndrome. Monitor for signs of pancreatitis (severe abdominal pain). Maintain adequate hydration—semaglutide can cause dehydration via reduced fluid intake.

Semaglutide purity is critical—impurities can worsen GI side effects and reduce efficacy. Ascension Peptides provides research-grade semaglutide and BPC-157 with:

• 99%+ purity verified by independent HPLC analysis
• Proper cold-chain shipping to maintain compound integrity
• Oral and injectable BPC-157 options available

Get your semaglutide and BPC-157 from Ascension Peptides to ensure your stack performs as expected.